Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Osborne Partners Capital Management LLC

Osborne Partners Capital Management LLC grew its position in Bristol-Myers Squibb (NYSE:BMY) by 0.3% during the third quarter, Holdings Channel reports. The firm owned 94,249 shares of the biopharmaceutical company’s stock after acquiring an additional 259 shares during the period. Osborne Partners Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $4,876,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. ESL Trust Services LLC acquired a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. LGT Financial Advisors LLC lifted its stake in Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares during the period. ORG Wealth Partners LLC purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $34,000. MFA Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the second quarter worth $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Bristol-Myers Squibb during the second quarter valued at $42,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. TD Cowen increased their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft dropped their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a research note on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $53.31.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $51.92 on Friday. The firm has a market cap of $105.25 billion, a P/E ratio of -16.75, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. The stock has a 50 day moving average of $50.75 and a two-hundred day moving average of $46.44. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $55.29. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same period in the prior year, the company earned $1.75 EPS. The firm’s revenue was up 8.7% compared to the same quarter last year. On average, analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.62%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.